169 related articles for article (PubMed ID: 31683867)
1. ER-Negative Breast Cancer Is Highly Responsive to Cholesterol Metabolite Signalling.
Hutchinson SA; Lianto P; Roberg-Larsen H; Battaglia S; Hughes TA; Thorne JL
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31683867
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional regulation of mixed lineage kinase 3 by estrogen and its implication in ER-positive breast cancer pathogenesis.
Viswakarma N; Nair RS; Sondarva G; Das S; Ibrahimi L; Chen Z; Sinha S; Rana B; Rana A
Oncotarget; 2017 May; 8(20):33172-33184. PubMed ID: 28388540
[TBL] [Abstract][Full Text] [Related]
3. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
[TBL] [Abstract][Full Text] [Related]
4. Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor.
Morrison AJ; Herrera RE; Heinsohn EC; Schiff R; Osborne CK
Mol Endocrinol; 2003 Aug; 17(8):1543-54. PubMed ID: 12730327
[TBL] [Abstract][Full Text] [Related]
5. CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer.
van Agthoven T; Sieuwerts AM; Veldscholte J; Meijer-van Gelder ME; Smid M; Brinkman A; den Dekker AT; Leroy IM; van Ijcken WF; Sleijfer S; Foekens JA; Dorssers LC
Br J Cancer; 2009 Dec; 101(11):1824-32. PubMed ID: 19904269
[TBL] [Abstract][Full Text] [Related]
6. Cholesterol and breast cancer pathophysiology.
Nelson ER; Chang CY; McDonnell DP
Trends Endocrinol Metab; 2014 Dec; 25(12):649-55. PubMed ID: 25458418
[TBL] [Abstract][Full Text] [Related]
7. Liver × receptor ligands disrupt breast cancer cell proliferation through an E2F-mediated mechanism.
Nguyen-Vu T; Vedin LL; Liu K; Jonsson P; Lin JZ; Candelaria NR; Candelaria LP; Addanki S; Williams C; Gustafsson JÅ; Steffensen KR; Lin CY
Breast Cancer Res; 2013 Jun; 15(3):R51. PubMed ID: 23809258
[TBL] [Abstract][Full Text] [Related]
8. Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator.
Hudelist G; Czerwenka K; Kubista E; Marton E; Pischinger K; Singer CF
Breast Cancer Res Treat; 2003 Mar; 78(2):193-204. PubMed ID: 12725419
[TBL] [Abstract][Full Text] [Related]
9. The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous tissue.
Chong YM; Colston K; Jiang WG; Sharma AK; Mokbel K
Breast Cancer Res Treat; 2006 Oct; 99(3):275-88. PubMed ID: 16752221
[TBL] [Abstract][Full Text] [Related]
10. AR-PDEF pathway promotes tumour proliferation and upregulates MYC-mediated gene transcription by promoting MAD1 degradation in ER-negative breast cancer.
Cao L; Xu C; Xiang G; Liu F; Liu X; Li C; Liu J; Meng Q; Jiao J; Niu Y
Mol Cancer; 2018 Sep; 17(1):136. PubMed ID: 30217192
[TBL] [Abstract][Full Text] [Related]
11. Scaffold attachment factor SAFB1 suppresses estrogen receptor alpha-mediated transcription in part via interaction with nuclear receptor corepressor.
Jiang S; Meyer R; Kang K; Osborne CK; Wong J; Oesterreich S
Mol Endocrinol; 2006 Feb; 20(2):311-20. PubMed ID: 16195251
[TBL] [Abstract][Full Text] [Related]
12. Nuclear Receptors Are Differentially Expressed and Activated in KAIMRC1 Compared to MCF7 and MDA-MB231 Breast Cancer Cells.
Nehdi A; Ali R; Alhallaj A; Alzahrani H; Samman N; Mashhour A; Baz O; Barhoumi T; Alghanem B; Khan A; Alriyees L; Boudjelal M
Molecules; 2019 May; 24(11):. PubMed ID: 31141879
[TBL] [Abstract][Full Text] [Related]
13. Role of estrogen receptor ligand and estrogen response element sequence on interaction with chicken ovalbumin upstream promoter transcription factor (COUP-TF).
Klinge CM
J Steroid Biochem Mol Biol; 1999 Nov; 71(1-2):1-19. PubMed ID: 10619353
[TBL] [Abstract][Full Text] [Related]
14. Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones.
Havrilesky LJ; McMahon CP; Lobenhofer EK; Whitaker R; Marks JR; Berchuck A
J Soc Gynecol Investig; 2001; 8(2):104-13. PubMed ID: 11336882
[TBL] [Abstract][Full Text] [Related]
15. Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells.
Lim JT; Joe AK; Suzui M; Shimizu M; Masuda M; Weinstein IB
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3478-84. PubMed ID: 16740773
[TBL] [Abstract][Full Text] [Related]
16. The cholesterol metabolite 27-hydroxycholesterol regulates p53 activity and increases cell proliferation via MDM2 in breast cancer cells.
Raza S; Ohm JE; Dhasarathy A; Schommer J; Roche C; Hammer KD; Ghribi O
Mol Cell Biochem; 2015 Dec; 410(1-2):187-95. PubMed ID: 26350565
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
[TBL] [Abstract][Full Text] [Related]
18. Estrogen receptors: selective ligands, partners, and distinctive pharmacology.
Katzenellenbogen BS; Montano MM; Ediger TR; Sun J; Ekena K; Lazennec G; Martini PG; McInerney EM; Delage-Mourroux R; Weis K; Katzenellenbogen JA
Recent Prog Horm Res; 2000; 55():163-93; discussion 194-5. PubMed ID: 11036937
[TBL] [Abstract][Full Text] [Related]
19. How to target estrogen receptor-negative breast cancer?
Rochefort H; Glondu M; Sahla ME; Platet N; Garcia M
Endocr Relat Cancer; 2003 Jun; 10(2):261-6. PubMed ID: 12790787
[TBL] [Abstract][Full Text] [Related]
20. A fusion protein of the estrogen receptor (ER) and nuclear receptor corepressor (NCoR) strongly inhibits estrogen-dependent responses in breast cancer cells.
Chien PY; Ito M; Park Y; Tagami T; Gehm BD; Jameson JL
Mol Endocrinol; 1999 Dec; 13(12):2122-36. PubMed ID: 10598586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
